Polychondritis Disease Treatment | Market Size, Share & Growth Report 2025-2033
The Polychondritis Disease Treatment Market Report is Segmented by Treatment Type (Nonsteroidal Anti-Inflammatory Drugs, Corticosteroids, Disease-Modifying Antirheumatic Drugs, Biologics, and Others), Route of Administration (Oral, Injectable, and Topical), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Disease Type (Relapsing Polychondritis, Systemic Polychondritis, and Atypical Polychondritis).
Polychondritis Disease Treatment Market
Market Analysis
How the market stands today, and what is shaping it
The global polychondritis disease treatment market was estimated at approximately USD 103.0 million in 2025 and is projected to reach around USD 182.34 million by 2033, representing a CAGR of approximately 7.40% during 2025–2033, based on Core Market Research estimates. The market covers nonsteroidal anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs and biologics, given orally and by injection and dispensed principally through hospital pharmacies. Growth is supported by a chronic relapsing condition requiring years of treatment, by off-label biologics carrying most of the value, by momelotinib holding Orphan Drug Designation for VEXAS syndrome with the Phase II/III ATLAS trial underway, and by genetic testing identifying patients since 2021. Expansion is constrained by prevalence of roughly 4.5 cases per million, by incidence measured at 0.71 per million population per year, and by the absence of any approved therapy, which leaves funding to individual decisions. North America leads on documented clinical and research concentration.
Market Dynamics
Key market dynamics and their impact on the industry landscape
Market Drivers
- Relapsing polychondritis is chronic and relapsing rather than self-limiting, so a patient identified once requires suppression of inflammation for years, which converts each diagnosis into sustained rather than episodic treatment.
- Biologics used off-label, including interleukin-6 and interleukin-1 inhibitors and JAK1/2 inhibitors, carry most of this market's value, and reported series indicate interleukin-6 and JAK inhibitors produce more durable responses than other glucocorticoid-sparing options.
- GSK's momelotinib holds Orphan Drug Designation in both the United States and European Union for VEXAS syndrome, with the Phase II/III ATLAS trial underway, which is the clearest route to the first approved therapy in this space.
- Orphan designation brings development incentives and, if an approval follows, pricing appropriate to a disease affecting roughly 4.5 people per million, which would raise revenue per patient far above current off-label generic-based treatment.
- Tracheobronchial involvement determines prognosis and concentrates care in specialist centres with bronchoscopy and airway intervention capability. Those centres support higher-intensity treatment for the patients who need it most, which is where this market's spending is concentrated.
Market Challenges
- No therapy is approved specifically for relapsing polychondritis or VEXAS syndrome, so the entire market runs on off-label prescribing, which leaves funding to individual decisions rather than standing reimbursement policy.
- The disease occurs at roughly 4.5 cases per million with incidence measured at 0.71 per million population per year, so the patient base is among the smallest of any market in this corpus and cannot expand through prevalence.
- Corticosteroids reach almost every patient and generate almost no revenue, while biologics treat a minority and carry most of the value, which makes market size depend on biologic access rather than on how many people have the disease.
- Two of the three supplied disease types, Systemic Polychondritis and Atypical Polychondritis, do not correspond to recognised diagnostic entities, so that segmentation cannot be used to divide the patient population meaningfully.
- Topical administration appears among the supplied routes although a topical preparation cannot reach inflamed cartilage in the ears, nose, airway or joints, which makes that category inapplicable rather than merely small.
Opportunities
- An approval following the Phase II/III ATLAS trial would create the first licensed therapy in this indication, converting off-label prescribing funded case by case into reimbursed treatment with orphan pricing.
- Pacritinib is under evaluation in the randomised placebo-controlled Phase 2 PAXIS trial, and a second targeted agent would establish a competitive category where none currently exists.
- Genetic testing for UBA1 mutations could be applied more systematically to men presenting over 45 with ear chondritis and systemic features, which would identify VEXAS patients who need different treatment from autoimmune relapsing polychondritis.
- Hypomethylating agents and allogeneic haematopoietic stem cell transplant have been described as promising in VEXAS, reflecting its myelodysplastic component and opening a treatment route unrelated to conventional immunosuppression.
- Asia Pacific holds the largest patient count by population at a prevalence affecting all racial groups equally, so improving off-label biologic access there would convert patients already diagnosed into treated ones.
Trends and Insights
Key market trends shaping the industry landscape
A Genetic Test Split the Disease
High impactLong-termSomatic UBA1 mutations were found in 7.6% of relapsing polychondritis patients, reclassifying them as having VEXAS syndrome.
Insight: Part of this market's historical patient population turned out to have a different disease with a myelodysplastic component, which means prior epidemiology and treatment evidence describe a mixed group rather than one condition.
Everything Is Off-Label
High impactMid-termNo therapy is approved specifically for relapsing polychondritis or VEXAS, and treatment relies on corticosteroids, conventional DMARDs and biologics used outside their licences.
Insight: Funding therefore depends on individual case decisions rather than standing policy, which makes this market's size a function of how readily payers approve exceptions rather than of clinical need.
The First Approval Is in Sight
High impactMid-termMomelotinib holds Orphan Drug Designation in the United States and European Union for VEXAS, with the Phase II/III ATLAS trial underway, and pacritinib is in the Phase 2 PAXIS trial.
Insight: A licensed orphan therapy would reprice the market rather than expand it, since the patient count is fixed by a prevalence of roughly 4.5 per million and only revenue per patient can move.
Most Patients Generate Almost No Revenue
Medium impactLong-termCorticosteroids reach nearly every patient while biologics treat a minority and carry most of the value.
Insight: Market size tracks biologic access rather than disease prevalence, so a forecast built from patient numbers will misread this market by a wide margin in either direction.
The Airway Decides the Outcome
Medium impactLong-termTracheobronchial cartilage involvement is the manifestation that determines prognosis and concentrates care in specialist centres.
Insight: Severity rather than diagnosis drives spending here, so the small subgroup with airway disease accounts for a disproportionate share of both clinical risk and treatment cost.
Segment Analysis
Market segmentation by treatment type, route of administration, distribution channel, disease type
Corticosteroids remain the backbone of treatment and reach almost every patient, but they generate very little revenue because prednisone is among the cheapest medicines in use. Biologics account for most of the market's value while treating a minority of patients, and they are used entirely off-label, with interleukin-6 and interleukin-1 inhibitors alongside JAK1/2 inhibitors serving as glucocorticoid-sparing options. Reported series indicate interleukin-6 inhibitors and JAK inhibitors produce more durable responses than the alternatives. Disease-Modifying Antirheumatic Drugs such as methotrexate and azathioprine occupy the middle ground, cheap and widely used but rarely sufficient alone in severe disease. Nonsteroidal Anti-Inflammatory Drugs manage mild cartilage inflammation only. The commercial structure is therefore inverted against the clinical one: the treatment everyone receives is worth almost nothing.
Geography Analysis
Regional market analysis
North America
North America is the largest market here on documented clinical and research concentration rather than on a measured regional market size. The genetic work that reclassified part of this patient population originated here, with the 2021 finding that 7.6% of relapsing polychondritis patients carry somatic UBA1 mutations. Access to off-label biologics is also greatest in the region, which matters disproportionately because biologics carry most of this market's value while treating a minority of patients. Specialist centres capable of managing tracheobronchial involvement are concentrated here. No regional market size, revenue or growth figure was identified for any region in this market, and no company examined reports polychondritis revenue separately, so both regional rankings are documented judgements.
Europe
Europe provided the epidemiological foundation for understanding how rare this disease is, through a United Kingdom population-based cohort reporting incidence of 0.71 per million population per year between 1990 and 2012. GSK holds the most advanced targeted programme from the United Kingdom, with momelotinib carrying Orphan Drug Designation in the European Union as well as the United States, and Swedish Orphan Biovitrum supplies from Sweden. Off-label biologic access varies considerably between national health systems, since paying for an unlicensed indication in a disease this rare depends on individual funding decisions rather than standing policy. No European market size, revenue or growth figure was identified.
Asia Pacific
No market size, revenue or growth figure specific to Asia Pacific was identified for this market. Relapsing polychondritis affects all racial groups at a prevalence of roughly 4.5 per million, so the region's patient numbers follow its population rather than any epidemiological difference, making it the largest patient pool by count. Japan has contributed substantially to the clinical literature, including longitudinal observation of interleukin-6 inhibition in VEXAS-associated disease. The constraint on realised value is access to off-label biologics, which varies widely across the region and determines whether a patient receives inexpensive corticosteroids or a high-cost agent.
Latin America
No market size, revenue or access figure specific to Latin America was identified for this market. Diagnosis is the binding constraint rather than treatment, because a disease occurring at roughly 4.5 per million is easily missed and its early features, inflamed ear cartilage and joint pain, are readily attributed to other causes. Where patients are identified, corticosteroids and conventional DMARDs are affordable and available, while off-label biologics are largely confined to private healthcare. The gap between the patient population and the treated population is wider here than in higher-income regions.
Middle East & Africa
No market size, revenue or access figure specific to the Middle East and Africa was identified for this market. Gulf states operate rheumatology services capable of diagnosing the condition and funding off-label biologic therapy for individual patients. Across much of Africa, a disease at roughly 4.5 per million with features overlapping commoner conditions is unlikely to be formally diagnosed, and genetic testing for UBA1 mutations is not routinely available. The region contributes very little to this market's value while carrying a patient population proportionate to its size.
Competitive Landscape
Key players and market positioning analysis
No company markets an approved product for this disease, so the participants are those whose agents are used off-label and those developing the first licensed therapy. GSK plc holds the most advanced position through momelotinib, which carries Orphan Drug Designation in both the United States and the European Union for VEXAS syndrome and is in the Phase II/III ATLAS trial intended to support regulatory filing. Roche Holding AG participates through interleukin-6 inhibition, which reported series place among the more durable glucocorticoid-sparing options, and which has been studied longitudinally in VEXAS-associated relapsing polychondritis in Japan. Swedish Orphan Biovitrum AB is positioned across both sides of this market, supplying interleukin-1 inhibition and holding pacritinib, which is in the randomised placebo-controlled Phase 2 PAXIS trial for VEXAS. AbbVie Inc. participates through tumour necrosis factor inhibition and JAK inhibition used off-label in inflammatory disease generally. Incyte Corporation's ruxolitinib is used in VEXAS on the same basis. None of these companies developed its agent for this indication, and all reached it through disease adjacency rather than intent, which is characteristic of conditions too rare to justify a dedicated programme until orphan incentives change the calculation. Competitive outcomes will be decided by which agent reaches approval first and how durable its responses prove against corticosteroid tapering.
Major Players
Leading companies in the market
Industry Developments
5 recorded developments
GSK's momelotinib received Orphan Drug Designation in both the United States and the European Union for VEXAS syndrome, with the Phase II/III ATLAS trial underway to support future regulatory filing. No therapy is yet approved specifically for this indication.
Pacritinib entered evaluation in the randomised placebo-controlled Phase 2 PAXIS trial for VEXAS syndrome. Interleukin-6 inhibitors and JAK inhibitors have shown more durable responses than other glucocorticoid-sparing options in reported series.
Work published in Arthritis & Rheumatology found that 7 of 92 patients with relapsing polychondritis, or 7.6%, carried somatic UBA1 mutations. Those patients were all male, typically at least 45 at onset, with fever, ear chondritis, skin involvement, deep vein thrombosis and pulmonary infiltrates.
VEXAS syndrome was established as a distinct entity defined by somatic UBA1 variants producing severe systemic inflammation alongside myelodysplastic syndrome. A proportion of patients previously diagnosed with relapsing polychondritis were shown to have a different disease entirely.
A United Kingdom population-based cohort study reported the incidence of relapsing polychondritis between 1990 and 2012 at 0.71 per million population per year, with a 95% confidence interval of 0.55 to 0.91, establishing how few patients this market serves.
Table of Contents
13 comprehensive chapters
1.1 Market Definition
1.2 Scope of the Study
1.3 Research Objectives
2.1 Research Approach
2.2 Data Sources
2.3 Market Estimation Approach
2.4 Forecast Assumptions
2.5 Research Limitations
3.1 Market Overview
3.2 Market Size and Forecast
3.3 Key Findings
3.4 Market Structure
4.1 Market Drivers
4.2 Market Challenges
4.3 Market Opportunities
4.4 Market Trends and Insights
5.1 Market Segmentation Overview
5.2 By Treatment Type
5.3 By Route of Administration
5.4 By Distribution Channel
5.5 By Disease Type
6.1 North America
6.2 Europe
6.3 Asia Pacific
6.4 Latin America
6.5 Middle East & Africa
6.6 Regional Market Comparison
7.1 Industry Developments
7.2 Industry Timeline
8.1 Market Structure and Competitive Positioning
8.2 Major Players
8.3 Strategic Developments
8.4 Key Competitive Factors
9.1 GSK plc
9.2 Roche Holding AG
9.3 Swedish Orphan Biovitrum AB
9.4 AbbVie Inc.
9.5 Incyte Corporation
10.1 Market Size and Growth Outlook
10.2 Regional Market Outlook
10.3 Future Market Trends
10.4 Key Risks to the Forecast
11.1 Growth Opportunities
11.2 Key Risks and Constraints
11.3 Strategic Considerations
13.1 Glossary of Terms
13.2 Abbreviations
13.3 Research References
Scope of the Report
Report coverage and methodology
Study Period
Base Year: 2025
Forecast Period: 2025 - 2033
Geographic Scope
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Covered
GSK plc, Roche Holding AG, Swedish Orphan Biovitrum AB, AbbVie Inc. + more
Data Sources
Primary research, industry interviews, regulatory filings, company reports
Frequently Asked Questions
Common questions about this report
Ready to Get the Full Report?
Access comprehensive market insights, detailed analysis, and strategic recommendations to make informed business decisions.